Lehigh Valley Hospital-Hazelton
Clinical research site in Hazleton, Pennsylvania · 700 E BROAD ST, HAZLETON, PA 18201-6835 · (570) 501-4000
As of September 2026, 35 paid clinical trials are recruiting at Lehigh Valley Hospital-Hazelton in Hazleton, Pennsylvania. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Malignant Solid Neoplasm and Advanced Esophageal Adenocarcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at Lehigh Valley Hospital-Hazelton (35)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Family Communications After Genetic Testing
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Get new-trial alerts for Lehigh Valley Hospital-Hazelton
We'll email you whenever a new clinical trial starts recruiting at this research site in Hazleton, PA. Unsubscribe anytime.
More research sites in Hazleton
- Lehigh Valley Hospital-Hazleton (33 trials)
- Geisinger Medical Center-Cancer Center Hazleton (19 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.
Explore more
Paid clinical trials in Hazleton, PA · Pennsylvania clinical trials